

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/271466 A1

(51) International Patent Classification:

C07K 14/435 (2006.01) C07K 19/00 (2006.01)
A61K 38/30 (2006.01) C12N 15/12 (2006.01)
C07K 14/65 (2006.01)

(21) International Application Number:

PCT/US2022/033059

(22) International Filing Date:

10 June 2022 (10.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/259,088 21 June 2021 (21.06.2021) US

(71) Applicant: JUVENA THERAPEUTICS, INC. [US/US];
640 Galveston Drive, Redwood City, CA 94603 (US).

(72) Inventors: YOUSEF, Hanadi; 229 A Street, Redwood
City, CA 94063 (US). O'CONNELL, Jeremy; 905 Clark
Way, Palo Alto, CA 94304 (US). MAI, Thach; 110 Long-

ford Drive, South San Francisco, CA 94080 (US). LI, Zhi-
hua; 3998 Hamilton Park Drive, San Jose, CA 95310 (US).


(74) Agent: KUMAMOTO, Andrew; Helixip LLP, 1935 Bel-
mont Avenue, San Carlos, CA 94070 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: REGENERATIVE POLYPEPTIDES AND USES THEREOF

FIG 1A



(57) Abstract: Described herein are polypeptides comprising an IGF 2 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Mutations within the IGF2 amino acid sequence improved the stability of the molecule by reducing backbone cleavage. Also described herein are synergistic combinations of an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*